Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Nurix Therapeutics, Inc. is placed second on our list.

TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintained a Buy rating. The firm noted that 2026 will be a key year for bexobrutideg as management progresses two registrational trials and provides additional Phase 1 updates.

In contrast, on the same day, Wells Fargo lowered the price target on Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $29 from $30 and maintained an Overweight rating. The firm points out that even in the absence of clinical triggers in 2026, the shares are still cheap and could increase in the second half of the year before significant catalysts in 2027.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a biopharmaceutical company that develops targeted protein modulation therapies using its proprietary DELigase platform. NRIX focuses on ubiquitin signaling pathways in order to develop degraders and small-molecule programs for immunology and oncology illnesses and develops precision medicines to address unmet medical needs and enhance patient outcomes.

While we acknowledge the potential of NRIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.